RetinaCME
EXPERT INTERVIEWCMEABO MOC

Eye On Expanding Surgical Systems That Lengthen Treatment Intervals in nAMD and DME

Author(s)/Faculty: Carl C. Awh, MD; Jordan M. Graff, MD, FACS, FABO
Release Date: 11/22/2021Expiration Date: 11/21/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.75
Content Type: VideoProvider:
Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the management paradigm for patients with retinal vascular diseases, yet there is still an unmet need to address treatment burden and loss of patient adherence due to dosing schedules. For patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), there is ongoing evaluation of gene therapy and sustained delivery devices, as they provide the potential to extend treatment intervals while maintaining visual acuity. These advances in treatment delivery require unique surgical approaches for optimal efficacy outcomes and safety. In this CME activity, experts in the field review emerging surgical delivery systems that allow for the management of nAMD and DME over an extended period of time as well as evaluate novel surgical techniques and best practices for reducing potential complications.